Clinical trialPhase 2Recruiting
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 26 August 2010
- Expected end
- 27 December 2029
- Enrollment
- 332 participants
- Sites
- 1
- Primary outcomes
- Response rate
- Sponsor
- Nih
- Results posted
- No
- Last update
- 23 October 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 5
- Builds on itNeoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. DOI 10.1038/s41591-025-03627-5↗
- Builds on itNeoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while p… DOI 10.1136/jitc-2023-008645↗
- Builds on itBreast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autolo… DOI 10.1200/jco.21.02170↗
- Builds on itNeoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. DOI 10.1172/jci123791↗
- Builds on itCancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. DOI 10.1126/science.1251102↗